Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
1. CORT's ROSELLA trial met primary endpoint for ovarian cancer treatment. 2. Combination treatment showed 30% reduced risk of disease progression. 3. Median progression-free survival improved from 5.5 to 6.5 months. 4. Overall survival significantly increased to 16 months versus 11.5 months. 5. Analysts raised price targets, reflecting strong market confidence.